Serum tissue polypeptide specific antigen (TPS): A complementary tumor marker to CA 15-3 in the management of breast cancer

Breast Cancer Research and Treatment

Volumn 68, Issue 1, 2001, Pages 9-19

  D'Alessandro, R ^a   Roselli, M ^b   Ferroni, P ^c   Mariotti, S ^a   Spila, A ^a   Aloe, S ^a   Carone, M D ^a   Abbolito, M R ^a   Carlini, S ^a   Perri, P ^a   Ricciotti, A ^a   Botti, C ^a   Conti, F ^a   Vici, P ^a   Chiappetta, N R ^a   Cognetti, F ^a   Buonomo, O ^b   Guadagni, F ^a  

^a S EUGENIO HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast benign diseases; Breast cancer; CA 15 3; Cytokeratins, follow up; Neoadjuvant chemotherapy; Serum tumor markers; Tissue polypeptide specific antigen (TPS)

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FLUOROURACILE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PATIENT MONITORING; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; ITALY; LONGITUDINAL STUDIES; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEPTIDES; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 17944376143     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017903724176     Document Type: Article

References (48)

1. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer
2. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer
3. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients
4. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma
5. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients
6. Breast cancer and clinical utility of CA 15-3 and CEA
7. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors
8. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients
9. c-erbB-2 oncoprotein, CEA, and CA 15-3 in patients with breast cancer: Prognostic value
10. Demonstration of tumor-specific antigens in human colonic carcinomata by immunologic tolerance and absorption techniques
11. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in breast cancer
12. Comparison of CA15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer
13. Value of CA15.3 in the follow-up of breast cancer patients
14. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
15. The value of the tumor marker CA15.3 in diagnosis and monitoring breast cancer
16. A reevaluation of CEA as serum marker for breast cancer - A prospective longitudinal study
17. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients
18. Circulating tumor markers in breast cancer
19. Comparison of circulating CA 15-3 and CEA levels in patients with breast cancer
20. CA 15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer
21. CA 549 as a marker in breast cancer
22. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18
23. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18
24. Antigenicity of a pooled human malignant and normal tissues by cyto-immunological technique. Presence of an insoluble, heat-labile tumor antigen
25. Clinical evaluation of serum tissue polypeptide specific antigen in non-small cell lung cancer
26. Cytokeratin markers in malignant pleural mesothelioma
27. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma
28. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer
29. Serum markers for monitoring of prostatic carcinoma
30. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients
31. TPS in breast cancer - A comparative study with carcinoembryonic antigen and CA 15-3
32. The clinical value of serum tissue polypeptide specific antigen (TPS) in breast cancer patients
33. The value of TPS in breast cancer
34. TPS and CA 15-3 serum values as a guide for treating and monitoring breast cancer patients
35. Tissue polypeptide specific antigen (TPS) in breast cancer - An initial evaluation
36. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer
37. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease
38. TPS monitoring in metastatic breast cancer
39. CA549 and TPS patterns in the diagnosis and staging of patients with breast carcinoma
40. Clinical value of CYFRA 8/18 and TPS in the diagnosis and follow up of invasive breast cancer
41. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer
42. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen
43. Clinical utility of CA 72-4 serum marker in the staging and immediate postsurgical management of gastric cancer patients
44. Expression of cytokeratins in regenerating human epidermis
45. Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients
46. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease
47. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumor marker changes
48. The correlation of CA 15-3 and TPS with tumor course in patients with metastatic breast cancer